Bicycle Therapeutics

What is Bicycle Therapeutics?

Bicycle Therapeutics is a pioneering biotechnology firm located at the Babraham Research Campus in Cambridge, U.K., with additional operations in the United States.

They are dedicated to the advancement of a distinctive technology platform aimed at creating a new class of biotherapeutics. Bicycle's technology cleverly blends the favorable attributes of small molecules with those of biopharmaceuticals.

Stemming from foundational discoveries at the MRC Laboratory of Molecular Biology in Cambridge by co-founders Professor Christian Heinis and Sir Gregory Winter, the company has refined their approach into a robust platform under Dr. John Tite's leadership as Chief Scientific Officer (CSO).

Impressively, Bicycle Therapeutics is financially bolstered by reputable investment bodies, including Atlas Venture, Novartis Venture Fund, SV Life Sciences, and SR One. Their mission is crystal clear: to conceive and deliver unique, impactful medicines that have the power to significantly alter the lives of a vast number of patients through precision-guided therapeutics.

While their primary focus currently lies in targeting solid tumor cancers, they also recognize the expansive potential of their technology. Engaging in partnerships, they advance beyond oncology to tackle a myriad of medical challenges in other domains, such as anti-infective, cardiovascular, ophthalmology, dementia, central nervous system, neuromuscular, and respiratory sectors.

Bicycle Therapeutics is aggressively exploring novel therapeutic applications and potential collaborations to leverage their platform in the quest to conquer complex diseases with unfulfilled medical needs. They firmly believe in their state-of-the-art modality's potential to modulate a broad spectrum of elusive yet valuable targets.